Skip to main content

What the FDA labels say about taking them together

Methotrexate and sepiapterin

Sepiapterin's FDA label of April 24, 2026 names methotrexate in its drug interactions section; the methotrexate labels PlainMeds reads (4) do not name sepiapterin. The sepiapterin label: “DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use. Sepiapterin Reductase (SR) Inhibitors:”

Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the sepiapterin FDA label on DailyMed (effective April 24, 2026, PTC Therapeutics Inc.).

What does the methotrexate label say about sepiapterin?

Methotrexate's label (effective May 27, 2026) and its 3 other brand-application labels do not name sepiapterin in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed

What does the sepiapterin label say about methotrexate?

Sepiapterin label, drug interactions

DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). ( 7.1 ) Sepiapterin Reductase (SR) Inhibitors:

Source: FDA drug label (Sephience), PTC Therapeutics Inc., effective April 24, 2026 (SPL set 32ac719c-49f0-4105-9c46-18c19583a5c2), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

29Methotrexate generic labelers
0Sepiapterin generic labelers
MethotrexateSepiapterin
Labeled forRheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancern/a
Boxed warningYesNo
Pharmacy cost (NADAC)$0.158 per tablet 2.5 mg tabletn/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?